SHetA2 for Cervical Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Stephenson Cancer Center, Oklahoma City, OKCervical Cancer+2 MoreSHetA2 - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial is testing the safety of SHetA2, a potential new cancer treatment, in patients with recurrent cervical, ovarian, or endometrial cancer.

Eligible Conditions
  • Cervical Cancer
  • Ovarian Cancer
  • Endometrial Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

2 Primary · 10 Secondary · Reporting Duration: up to three years

21 days
Dosage Recommendation for Phase 2
Number of dose-limiting toxicities of treatment with SHetA2
24 hours
Plasma
Cmax of PK plasma concentration
Tmax of PK plasma concentration
t1/2 of PK plasma concentration
up to three years
Incidence of adverse events
Median duration of response
Median overall survival
Median progression free survival
Rate of disease control
Rate of objective response

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

SHetA2 capsule
1 of 1

Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: SHetA2 · No Placebo Group · Phase 1

SHetA2 capsule
Drug
Experimental Group · 1 Intervention: SHetA2 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to three years

Who is running the clinical trial?

University of OklahomaLead Sponsor
427 Previous Clinical Trials
98,682 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,163 Previous Clinical Trials
41,167,215 Total Patients Enrolled
Kathleen Moore, MDPrincipal InvestigatorStephenson Cancer Center
8 Previous Clinical Trials
340 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are additional volunteers being sought for this research endeavor?

"Indeed, according to clinicaltrials.gov the study is actively recruiting participants after being initially posted on June 27th 2022 and recently edited on July 7th 2022. The trial needs 50 volunteers from a single location for completion." - Anonymous Online Contributor

Unverified Answer

Has SHetA2 been granted authorization by the Food and Drug Administration?

"The safety of SHetA2 was rated a 1 on the scale due to it being in Phase 1 trials, and thus having sparse evidence regarding its effectiveness and potential side effects." - Anonymous Online Contributor

Unverified Answer

How many participants have been recruited for this experiment?

"Affirmative. Clinicaltrials.gov states that this medical trial is recruiting patients, which began on June 27th 2022 and was most recently updated on July 7th 2022. The study requires the recruitment of 50 individuals from a single site to participate in its research operations." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.